How We Treat Stomach Cancer

colorectal-and-colon-cancer-multidisciplinary-care-team-saint-johns-cancer-institute
A multidisciplianry team, including radiation oncolgy, surgical oncology, and medical oncology, are essential to maximize patient outcomes.

Stomach cancer treatment depends on the type and stage of disease, its location within the stomach, and the patient’s overall health. Options may include endoscopic procedures, surgery, chemotherapy, radiation therapy, immunotherapy, or targeted medications. At Saint John’s Health Center, multidisciplinary evaluation helps determine how these approaches may be used individually or together, while research at Saint John’s Cancer Institute works to maximize patient outcomes.

Our approach brings together expertise in gastrointestinal surgery, medical oncology, radiation oncology, gastroenterology, pathology, diagnostic imaging, and supportive care. Treatment planning also considers molecular testing, nutritional health, and the patient’s goals, helping guide decisions from initial treatment through recovery and follow-up.

Understanding Stomach Cancer Treatment

Most stomach cancers are adenocarcinomas, which arise from glandular cells in the stomach lining. Treatment depends on how deeply the tumor has grown into the stomach wall, whether nearby lymph nodes contain cancer, and whether disease has spread to distant sites. Some very early cancers can be removed through endoscopy, while others require surgery and additional treatment. Advanced or metastatic cancer is generally managed primarily with systemic therapy, along with procedures to relieve symptoms when needed.

For many patients with localized but more advanced gastric cancer, chemotherapy before and after surgery is an established treatment approach. This is called perioperative chemotherapy. Selected patients may receive other treatment combinations based on their cancer’s characteristics, current evidence, and individual circumstances. Immunotherapy and targeted medications play increasingly important roles, particularly when molecular testing identifies specific biomarkers.

Stomach Cancer and Gastroesophageal Junction Cancer

The gastroesophageal junction (GEJ) is the area where the esophagus meets the stomach. Cancers that develop near this junction may involve the lower esophagus, upper stomach, or both. Their classification and treatment depend partly on the location of the tumor’s center, the extent of involvement, and the applicable staging system.

Some GEJ cancers are treated using approaches similar to those for gastric adenocarcinoma, including perioperative chemotherapy and surgery. Others may require treatment strategies more commonly associated with esophageal cancer, including chemoradiation followed by esophagectomy. The distinction matters because the surgical operation, reconstruction, and treatment sequence can differ.

For additional information about cancers involving the lower esophagus and gastroesophageal junction, please visit our Esophageal Cancer Treatment page.

To learn more about stomach cancer types, symptoms, risk factors, diagnosis, and staging, please visit our Stomach Cancer Conditions page.

Stomach Cancer Surgery

Surgery offers an opportunity for long-term disease control or cure in appropriately selected patients with localized stomach cancer. The operation depends on the tumor’s location, depth, extent, and relationship to the gastroesophageal junction. The goal is to remove the cancer with an appropriate margin of healthy tissue while preserving normal digestive function whenever medically feasible. Regional lymph nodes are generally removed and examined because lymph node involvement helps determine the extent of disease and the need for additional treatment.

Patients with more advanced but potentially removable stomach cancer often receive systemic therapy before surgery, followed by further treatment afterward. The sequence is determined by the clinical stage, tumor characteristics, overall health, and multidisciplinary evaluation. Some very early cancers may be treated endoscopically without removing part of the stomach.

Endoscopic Treatment for Early Stomach Cancer

Selected early stomach cancers confined to superficial layers of the stomach wall may be removed during endoscopy. Endoscopic submucosal dissection (ESD) allows specialists to remove certain lesions in one piece for detailed pathological examination. Endoscopic mucosal resection (EMR) may also be considered in selected circumstances. Suitability depends on tumor size, depth, appearance, cellular characteristics, and the likelihood of lymph node involvement.

Endoscopic treatment can preserve the stomach and avoid a major operation for appropriately selected patients. However, when pathology identifies deeper invasion, incomplete removal, or features associated with a meaningful risk of lymph node spread, additional surgery may be recommended. Follow-up endoscopy remains important after treatment.

Partial or Subtotal Gastrectomy

Partial gastrectomy removes the portion of the stomach containing the cancer, together with appropriate surrounding tissue and regional lymph nodes. The remaining stomach is then connected to the digestive tract to restore the passage of food. The exact reconstruction depends on the location of the removed tissue and the amount of stomach that remains.

Partial gastrectomy may be appropriate when the tumor can be completely removed while preserving enough of the stomach for useful digestive function. However, preserving stomach tissue is not appropriate when doing so would compromise cancer removal. Patients may experience changes in appetite, meal size, and digestion after surgery, even when a portion of the stomach is retained.

Total Gastrectomy

Total gastrectomy involves removing the entire stomach, generally with regional lymph nodes. It may be necessary when cancer involves a large portion of the stomach, affects multiple areas, or is located where partial removal would not provide adequate cancer clearance. After removal, the surgeon reconstructs the digestive tract by connecting the esophagus to the small intestine, commonly using a Roux-en-Y reconstruction.

Patients can continue eating and digesting food after total gastrectomy, but significant lifelong adjustments are required. Meals are generally smaller and more frequent, and nutritional monitoring becomes especially important. Because the stomach produces intrinsic factor needed for vitamin B12 absorption, lifelong vitamin B12 supplementation is generally required. Patients may also need monitoring or supplementation for iron, calcium, vitamin D, and other nutrients.

Minimally Invasive and Robot-Assisted Gastrectomy

Selected partial and total gastrectomies can be performed using laparoscopic or robot-assisted techniques. These procedures use cameras and specialized instruments introduced through smaller incisions, allowing surgeons to remove the tumor and reconstruct the digestive tract. In robot-assisted surgery, the surgeon controls the instruments from a console; the robotic system does not operate independently.

Minimally invasive approaches may reduce some postoperative burdens and support recovery in appropriately selected patients. However, open surgery remains important when tumor extent, anatomy, prior operations, or reconstruction requirements make it the safer choice. The primary considerations are complete cancer removal, appropriate lymph node evaluation, and patient safety rather than incision size alone.

Chemotherapy for Stomach Cancer

Chemotherapy uses medications that circulate throughout the bloodstream to treat cancer cells. It may be administered before surgery, afterward, or as the primary treatment for unresectable or metastatic stomach cancer. In patients with localized but more advanced gastric adenocarcinoma, chemotherapy before and after surgery can reduce recurrence risk and improve treatment outcomes compared with surgery alone in appropriate circumstances.

A commonly used perioperative regimen is FLOT, which combines fluorouracil, leucovorin, oxaliplatin, and docetaxel. Other combinations may be recommended when FLOT is not appropriate because of age, other medical conditions, potential side effects, or treatment goals. For metastatic disease, chemotherapy often involves fluoropyrimidine- and platinum-based medications, sometimes combined with immunotherapy or a targeted treatment according to tumor biomarkers.

Immunotherapy for Stomach Cancer

Immunotherapy helps the immune system recognize and attack cancer cells. Immune checkpoint inhibitors may be beneficial for selected patients with stomach or gastroesophageal junction adenocarcinoma. Treatment selection can depend on disease stage, prior treatment, and biomarkers such as PD-L1 expression and mismatch repair deficiency or high microsatellite instability (dMMR/MSI-H).

For eligible patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab may be combined with FLOT chemotherapy before and after surgery, followed by durvalumab alone. For patients with advanced or metastatic cancer, medications such as nivolumab or pembrolizumab may be incorporated into treatment when appropriate. Immunotherapy is not necessary for every patient and carries risks of immune-related side effects that require monitoring.

Targeted Therapy and Molecular Testing

Targeted therapies interfere with selected proteins or biological pathways involved in cancer growth. Their use depends on the cancer’s molecular characteristics and the patient’s treatment history. For advanced gastric adenocarcinoma, important biomarkers include HER2, PD-L1, mismatch repair deficiency or microsatellite instability, and CLDN18.2. Broad molecular profiling may identify additional findings that influence treatment selection or clinical trial eligibility.

Some HER2-positive stomach cancers may be treated with HER2-directed therapy, such as trastuzumab combined with chemotherapy and, in appropriate circumstances, immunotherapy. Other HER2-directed medications may be considered after disease progression. For selected HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction cancers, zolbetuximab combined with chemotherapy is another available treatment approach. These therapies are not appropriate for every patient, and their use requires careful review of the relevant biomarker findings.

Radiation Therapy for Stomach Cancer

Radiation therapy uses focused high-energy radiation to damage cancer cells. It may be considered in selected situations, including certain postoperative circumstances or when localized treatment is needed to relieve bleeding, pain, or obstruction. Radiation is sometimes combined with chemotherapy, but it is not routinely required for all patients undergoing surgery for stomach cancer.

Modern external-beam techniques, including intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), allow treatment planning around the tumor and nearby structures. Planning must account for organs such as the liver, kidneys, small intestine, and remaining stomach. The role of radiation depends on disease extent, previous treatment, and the overall plan developed by the oncology team.

Treatment of Advanced or Metastatic Stomach Cancer

When stomach cancer cannot be completely removed or has spread to distant organs or tissues, systemic therapy generally becomes the principal treatment approach. Chemotherapy, immunotherapy, and targeted medications may be used individually or in combination according to tumor biology, previous treatment, overall health, and patient preferences.

Procedures may also be recommended to relieve symptoms caused by advanced disease. Endoscopic treatment or radiation may help manage bleeding, while stenting or surgical bypass may be considered for selected patients with obstruction. Nutrition and symptom management remain important throughout treatment, and clinical trials may offer additional options when an appropriate study is available.

Intraperitoneal Chemotherapy and HIPEC

Some stomach cancers spread to the peritoneum, the thin lining of the abdominal cavity. This pattern of spread is called peritoneal metastasis and can cause abdominal swelling, discomfort, bowel obstruction, or other complications. Systemic therapy remains an established treatment approach, while regional treatments delivered directly into the abdominal cavity continue to be investigated.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

HIPEC involves circulating heated chemotherapy within the abdominal cavity, generally during an operation. It may be performed after cytoreductive surgery, which removes visible tumor deposits from the abdominal lining. The objective is to treat microscopic disease remaining in the peritoneal cavity, although treatment cannot reliably eliminate every cancer cell.

For gastric cancer with peritoneal metastases, the benefits and appropriate indications for cytoreductive surgery and HIPEC remain under investigation. These procedures are not routine treatment for all patients with metastatic stomach cancer and should not be described as guaranteeing improved survival or cure. Selected patients may be considered for specialized evaluation or clinical trials based on disease burden, response to systemic therapy, overall health, and other factors.

Other Intraperitoneal Treatment Approaches

Intraperitoneal (IP) chemotherapy delivers anticancer medication directly into the abdominal cavity, sometimes through an implanted catheter. Other investigational techniques include pressurized intraperitoneal aerosol chemotherapy (PIPAC), which distributes chemotherapy within the abdominal cavity during a minimally invasive procedure. These approaches differ in drug delivery, treatment goals, and supporting evidence.

For stomach cancer, intraperitoneal treatment is not an established substitute for systemic chemotherapy, immunotherapy, or other recommended treatments. Its possible role is generally considered within specialized programs or clinical studies, with attention to potential complications and uncertain long-term benefits.

Recovery and Side Effects of Stomach Cancer Surgery

Gastrectomy is a major operation that changes the structure and function of the digestive tract. Although surgical techniques and perioperative care have advanced, complications can still occur. The risks depend on the extent of surgery, the patient’s underlying health, prior treatment, and the complexity of reconstruction. Patients should discuss expected recovery, possible complications, and long-term nutritional changes with their surgical team before treatment.

Possible Surgical Complications

Potential complications include bleeding, infection, blood clots, pneumonia, and problems with healing. Leakage from a connection between the remaining digestive structures, known as an anastomotic leak, is an important complication that may require additional treatment. Some patients also experience delayed bowel function, difficulty eating, or temporary changes in digestion.

Recovery varies considerably. Patients are monitored after surgery for pain, hydration, bowel function, nutrition, and signs of complications. Oral intake is often resumed gradually according to the patient’s condition and the surgical team’s recovery protocol. Prolonged fasting is not automatically required after every gastrectomy, and some patients may begin carefully supervised oral intake relatively early in recovery.

Diet and Nutrition After Gastrectomy

Nutrition and dietary guidance following stomach cancer surgery
Nutrition specialists can help patients adjust their eating habits and monitor nutritional deficiencies following partial or total gastrectomy.

After partial or total gastrectomy, patients commonly need to eat smaller meals more frequently because the stomach’s capacity to store food has been reduced or eliminated. The extent of dietary changes depends on the operation, reconstruction, and individual recovery. Patients may be advised to eat slowly, chew thoroughly, prioritize adequate protein and calories, and adjust fluid intake around meals when needed.

Some patients develop dumping syndrome, in which food passes rapidly into the small intestine. Symptoms may include abdominal cramping, diarrhea, dizziness, sweating, or changes in blood sugar after eating. Dietary adjustments can help manage these symptoms, although additional evaluation or treatment may be needed when they persist.

Vitamin and Mineral Supplementation

Gastrectomy can affect the absorption of vitamin B12, iron, calcium, vitamin D, and other nutrients. Following total gastrectomy, lifelong vitamin B12 supplementation is generally necessary because the stomach no longer produces intrinsic factor, which is required for normal vitamin B12 absorption. Patients who undergo partial gastrectomy may also develop nutritional deficiencies and require monitoring or supplementation.

Regular follow-up may include laboratory testing, dietary assessment, and individualized recommendations from a registered dietitian. In some circumstances, temporary enteral feeding through a tube placed into the small intestine may help maintain adequate nutrition during recovery.

Long-Term Follow-Up and Quality of Life

Long-term care after stomach cancer treatment includes monitoring for recurrence, nutritional deficiencies, changes in weight, digestive symptoms, and treatment-related complications. Follow-up may involve clinical visits, imaging, blood tests, and endoscopic evaluation when appropriate. The schedule depends on the original cancer stage, treatments received, and individual risk factors.

Supportive and palliative care can help patients manage pain, fatigue, appetite changes, anxiety, and other concerns during and after cancer treatment. These services can be provided alongside cancer-directed therapy and are not limited to patients with advanced disease.

saint-john's-health-center
Saint John’s Health Center in Santa Monica provides comprehensive stomach cancer treatment.

At Saint John’s Health Center, stomach cancer treatment planning brings together specialists in gastrointestinal surgery, medical oncology, radiation oncology, gastroenterology, pathology, and supportive care. This multidisciplinary approach helps patients understand their treatment options while addressing recovery, nutrition, and long-term health.

By considering the cancer’s characteristics, the patient’s health and treatment goals, and the effects of treatment on daily life, our team helps patients and families make informed decisions throughout care and recovery.

If you have questions about stomach of cancer or gastric treatments, please call today. Click here to request an appointment.